Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States

Clinical Therapeutics

Volumn 37, Issue 1, 2015, Pages 62-70

  LaMori, Joyce C ^a   Shoheiber, Omar ^b   Mody, Samir H ^a   Bookhart, Brahim K ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Tricore Interactive Inc   (United States)

Author keywords

Costs; Deep vein thrombosis; Length of stay; Pulmonary embolism

Indexed keywords

AGED; ANTICOAGULANT THERAPY; ARTICLE; DEEP VEIN THROMBOSIS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOME CARE; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; SEX DIFFERENCE; UNITED STATES; ADULT; COST; COST OF ILLNESS; ECONOMICS; FACTUAL DATABASE; HEALTH CARE COST; MIDDLE AGED; PULMONARY EMBOLISM; VENOUS THROMBOSIS; VERY ELDERLY;

ANTICOAGULANT AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CONTINUITY OF PATIENT CARE; COST OF ILLNESS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; UNITED STATES; VENOUS THROMBOSIS;

EID: 84920765628     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.10.024     Document Type: Article

References (16)

1. Cohen AT. Long-term benefits of preventing venous thromboembolic events. Curr Med Res Opin. 2012;28:877-889. [Erratum in: Curr Med Res Opin. 2012;28:1574.].
2. Go AS, Mazaffarian D, Roger VL, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2013;129:e28-e292.
3. Stein PD, Matta F. Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin. 2011;27:907-932.
4. Lefebvre P, Laliberté F, Nutescu EA, et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm. 2012;18:363-374.
5. McManus R, Fitzmaurice D, Murray E, Taylor C. Thromboembolism. Am Fam Physician. 2012;85:188-190.
6. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ. 2011;14:65-74.
7. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm. 2006;63(Suppl 6):S5-S15.
8. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13:475-486.
9. Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm. 2005;11:663-673.
10. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e419S-e494S.
11. Rymes NL, Lester W, Connor C, et al. Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clin Lab Haem. 2002;24:165-170.
12. Agency for Healthcare Research and Quality, Rockville, MD, USA. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). June 2013. www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed March 24, 2014.
13. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations-United States, 2007-2009. MMWR Morb Mortal Wkly Rep. 2012;61:401-404.
14. Mahon CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012;108:291-302.
15. Lin J, Lingohr-Smith M, Kwong WJ. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective. J Manag Care Pharm. 2014;20:174-186.
16. Monreal M, Suárez C, Fajardo J, et al. Management of patients with acute venous thromboembolism: findings from the RIETE registry. Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33:330-334.